LOS ANGELES, July 11, 2025 /PRNewswire/ -- PepsiCo (NASDAQ: PEP) is saddling up for summer with the launch of an exclusive collaboration with renowned streetwear brand Samii Ryan®. The Pepsi® x Samii Ryan capsule collection is a bold fusion of Y2K nostalgia, rodeo-core fashion, and the unmistakable flavor of PEPSI® Wild Cherry —dropping online on July 11, 2025. Designed to channel the fizzy spirit of summer and the freedom of self-expression, the collection features vintage-inspired denim jackets, graphic t ...

Whimsical, wearable, and trend-right - the collaboration spans Fall 2025 through Spring 2026 and beyond, delivering playful, collectible fashion moments for the modern familySECAUCUS, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- The Children’s Place, Inc. (Nasdaq: PLCE), the largest pure-play children’s specialty retailer in North America with an omni-channel portfolio of brands and an industry-leading digital-first model, today announced a new collaboration with global lifestyle brand, Sanrio®. The multi-season ...

| 招商通知 | | --- | | 第三届全球手术机器人大会 | | 第二届全球医疗科技大会 | 2025年7月1日 ， 专 注胶囊内窥镜技术创新的医疗科技公司 CapsoVision, Inc.（纳斯达克代码：CV） ，宣布其 首次公开募股 （IPO） 定价为每股 5.00 美元，共发行 550 万股普通股，预计募资 约2750万美元（约合人民币2亿） 。 股票于 7 月 2 日在纳斯达克 资本市场开始交易。这次发行不仅是融资事件，更意味着这家专注胃肠道诊断创新的公司，正试图在全球医疗市场中占据更重要的位 置。 CapsoVision 的首席执行官 Dean Burns 在公司发布会上表示："从一开始，我们的目标就是让胶囊内窥镜不仅能看见，更能看全。今 天的 IPO，是让我们更接近这个愿景的重要一步。" # 市 场与竞 争环 境 全球胶囊内窥镜市场预计到 2030 年将达到 12 亿美元。推动这一市场发展的核心动力是人口老龄化、消化道疾病患病率上升，以及人 们对非侵入性检查方式的偏好。特别是在结直肠癌筛查领域，随着人们预防意识增强，非侵入式检测的需求愈加迫切。 然而，CapsoVision 面对的竞争也异 ...

We're going to do a bit of a draft today. The five of us, we're going to pick five things each and it's going to be chaos and we're going to try to figure out what fictional tech do we want in our real lives. I'm going with the TARDIS from Doctor Who.Very good. Very good. My first pick is Capsules from Dragon Ball Z.I'm just going to take Jarvis from Iron Man. Oh, lost two already. Okay, just strategically, I think I need to grab the clueless closet.Surprised it took this long. I want kit. Okay, explain thr ...

They're on their way. They're looking at the parachutes. That's cool.You could see that from inside. What a cool shot of the booster and the capsule in one shot. That really just shows you how, you know, New Shepard is so reusable and, you know, just an incredible vehicle.And touchdown. Touchdown. ...

Beautiful landing site for the capsule. Oh yeah. Looks like it's going to be close to one of the roads, which is nice.Easy to get out there. There's a great shot actually of our crew recovery system. Yeah, they're on their way. They're looking at the parachutes.That's cool. You could see that from inside. What a cool shot of the booster and the capsule in one shot.That really just shows you how, you know, New Shepard is so reusable and, you know, just an incredible vehicle. And touchdown. Touchdown. ...

Core Insights - Neurocrine Biosciences announced significant reductions in cognitive and motor-related burdens in adults with Huntington's disease chorea treated with INGREZZA (valbenazine) capsules, based on new patient-reported post-hoc data from the KINECT-HD study [1][4] Group 1: Study Findings - The KINECT-HD study is the first clinical trial to show measurable changes in cognitive and motor disease burden with a vesicular monoamine transporter 2 inhibitor in Huntington's disease patients [1][2] - In the 12-week Phase 3 KINECT-HD clinical trial, INGREZZA showed a significant reduction in chorea severity, with a placebo-adjusted mean reduction in the Total Maximal Chorea (TMC) score of 3.2 units (p<0.0001) [11] - Patient-reported analyses indicated greater reductions in cognitive and motor-related disease burden for INGREZZA compared to placebo across various domains, including memory loss and mobility limitations [3][4] Group 2: Cognitive and Motor-Related Improvements - Statistically significant improvements were observed in cognition-related items, such as memory loss (-0.9 for INGREZZA vs -0.2 for placebo) and decision-making abilities (-1.0 for INGREZZA vs -0.3 for placebo) [3] - For motor-related items, INGREZZA demonstrated larger reductions in scores compared to placebo, including abnormal movements (-1.5 for INGREZZA vs -0.8 for placebo) and impaired coordination (-1.0 for INGREZZA vs -0.4 for placebo) [3][5] Group 3: Background on Huntington's Disease - Huntington's disease is a hereditary progressive neurodegenerative disorder affecting approximately 41,000 adults in the U.S., characterized by motor, cognitive, and psychiatric symptoms [7] - Chorea, a common symptom of Huntington's disease, involves irregular and unpredictable movements that can interfere with motor coordination and daily activities [7] Group 4: About INGREZZA - INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treating chorea associated with Huntington's disease and tardive dyskinesia [14][15] - The drug is designed for once-daily administration without the need for titration, making it convenient for patients [16]

The Industry Leader in CBD February 2024 Safe Harbor Statements & Disclaimers This presentation contains certain forward-looking statements that are based upon current expectations and involve certain risks and uncertainties within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as ''should,'' ''may,'' ''intends,'' ''anticipates,'' ''believes,'' ''estimates,'' ''projects,'' ''forecasts,'' ''expects,'' ''plan ...

🚨 BREAKING: SpaceX is set to launch Axiom Mission 4 on June 19 aboard Falcon 9 from Kennedy Space Center!This historic flight features astronauts from India, Poland, and Hungary, and will use a brand-new Crew Dragon capsule. https://t.co/rKDQdpSvdZ ...

KINECT-PRO is the first and only study to specifically evaluate and demonstrate patient-reported improvement with vesicular monoamine transporter 2 inhibitor treatment on tardive dyskinesia using multiple clinically validated scales Patients taking INGREZZA reported robust and clinically meaningful improvements in physical, social and emotional functioning Improvements were seen as early as Week 4 after initial treatment with the lowest INGREZZA dose and sustained through Week 24 Even patients with milder ...